# Salivary Gland Neoplasms: Workup and Classification

## Introduction

Salivary gland neoplasms represent a diverse group of tumors with a wide spectrum of biological behavior. They account for approximately **3-6% of all head and neck neoplasms**. The fundamental rule in salivary gland oncology is that the **smaller the gland, the higher the probability of malignancy**. A thorough understanding of classification, workup, and histopathology is critical for appropriate management.

## Anatomy Review

**Parotid gland**: largest salivary gland; Stensen duct opens opposite the second upper molar. **Submandibular gland**: Wharton duct opens at the sublingual caruncle. **Sublingual gland**: drains via multiple ducts of Rivinus into the floor of mouth. **Minor salivary glands**: 600-1000 distributed throughout the oral cavity, pharynx, larynx, and sinonasal tract; palate is the most common site of minor salivary gland tumors.

## Epidemiology

| Gland | % of All Salivary Neoplasms | % Malignant |
|-------|---------------------------|-------------|
| Parotid | 80% | 20% |
| Submandibular | 10-15% | ~50% |
| Sublingual | <1% | ~80% |
| Minor salivary glands | 10-15% | 50-80% |

**80% of salivary neoplasms** occur in the parotid gland. Of parotid tumors, **80% are benign**. Of submandibular tumors, approximately **50% are malignant**. Of minor salivary gland tumors, approximately **50-80% are malignant**. The **"80-80 rule"**: 80% of salivary tumors arise in the parotid, and 80% of those are benign.

## Classification of Salivary Gland Neoplasms

### Benign Tumors
**Pleomorphic adenoma (benign mixed tumor)**: most common salivary neoplasm overall (60-70%); composed of epithelial and mesenchymal elements; risk of malignant transformation (carcinoma ex pleomorphic adenoma) with prolonged observation. **Warthin tumor (papillary cystadenoma lymphomatosum)**: second most common benign parotid tumor; bilateral in 10-15%; more common in smokers and males. **Oncocytoma**: rare, composed of mitochondria-rich oncocytes. **Basal cell adenoma and canalicular adenoma**.

### Malignant Tumors
**Mucoepidermoid carcinoma**: most common malignant salivary neoplasm; low, intermediate, and high grade; low grade has excellent prognosis. **Adenoid cystic carcinoma**: characterized by **perineural invasion**; three patterns — cribriform (best prognosis), tubular, and solid (worst prognosis); late distant metastases (lung) even decades after treatment. **Acinic cell carcinoma**: low-grade malignancy; most common in the parotid. **Salivary duct carcinoma**: high-grade, aggressive; resembles ductal breast carcinoma; often **androgen receptor positive**. **Carcinoma ex pleomorphic adenoma**: arises within a longstanding pleomorphic adenoma; prognosis depends on extent of invasion beyond the capsule. **Adenocarcinoma NOS and polymorphous adenocarcinoma**.

![Histopathologic image of adenoid cystic carcinoma showing the classic cribriform pattern with pseudocystic spaces](/images/adenoid-cystic-histology.jpg)

## Clinical Presentation

**Painless mass** in the parotid, submandibular, or oral cavity region. **Pain**: suggests malignancy or infection but is not specific. **Facial nerve weakness**: highly suspicious for malignant parotid tumor. **Rapid growth**: concerning for high-grade malignancy or lymphoma. **Fixation** to skin or underlying structures: suggests malignancy. **Cervical lymphadenopathy**: present in 15-25% of malignant cases.

## Diagnostic Workup

### Imaging
**Ultrasound**: first-line; differentiates solid from cystic lesions; guides FNA. **CT with contrast**: assesses deep lobe tumors, bony invasion, nodal disease. **MRI with gadolinium**: superior soft tissue detail; evaluates perineural spread (adenoid cystic carcinoma). **PET-CT**: for staging high-grade malignancies.

### Fine Needle Aspiration (FNA)
**Sensitivity 85-95%, specificity 95-100%** for distinguishing benign from malignant. **Milan System for Reporting Salivary Gland Cytopathology**: standardized reporting categories (non-diagnostic, non-neoplastic, atypia of undetermined significance, benign, SUMP, suspicious, malignant). Core needle biopsy may be considered when FNA is non-diagnostic.

![Ultrasound-guided fine needle aspiration of a parotid gland mass](/images/parotid-fna-ultrasound.jpg)

## Staging (AJCC 8th Edition)

Based on **tumor size**, **extraparenchymal extension**, and involvement of adjacent structures. T1: <=2 cm, T2: 2-4 cm, T3: >4 cm or extraparenchymal extension, T4a/b: skin, mandible, ear canal, facial nerve, skull base invasion. Nodal staging follows standard head and neck N classification. **High-grade histology** is the most important prognostic factor independent of stage.

## Management Principles

**Benign tumors**: surgical excision (superficial or total parotidectomy with facial nerve preservation). **Malignant tumors**: surgery with appropriate margins +/- neck dissection +/- adjuvant radiation. **Facial nerve**: preserved unless directly invaded by tumor. **Adjuvant radiation**: indicated for high-grade histology, close/positive margins, perineural invasion, T3-T4, nodal disease. **Chemotherapy**: limited role; reserved for recurrent/metastatic disease. **Androgen receptor blockade**: emerging role for salivary duct carcinoma.

![MRI showing a deep lobe parotid pleomorphic adenoma extending through the stylomandibular tunnel into the parapharyngeal space](/images/deep-lobe-pleomorphic-mri.jpg)

## Key Clinical Pearls

The **smaller the gland, the higher the likelihood of malignancy** — always biopsy minor salivary gland lesions. Pleomorphic adenomas should be excised, not enucleated, due to pseudopod extensions through the capsule and risk of recurrence. Adenoid cystic carcinoma has a propensity for **perineural invasion** and late distant metastases; long-term follow-up (15-20 years) is essential. **Facial nerve paralysis** with a parotid mass is malignancy until proven otherwise. FNA is the initial tissue sampling modality of choice; incisional biopsy of parotid masses should be avoided.

## References

1. Speight PM, Barrett AW. Salivary gland tumours: diagnostic challenges and an update on the latest WHO classification. *Diagn Histopathol*. 2020;26(4):147-158.
2. Stodulski D, Mikaszewski B, Stankiewicz C. Signs and symptoms of parotid gland carcinoma and their prognostic value. *Int J Oral Maxillofac Surg*. 2012;41(7):801-806.
3. Rossi ED, Wong LQ, Bizzarro T, et al. The Milan System for Reporting Salivary Gland Cytopathology. *Cancer Cytopathol*. 2018;126(10):757-766.
4. Andreasen S, Therkildsen MH, Grauslund M, et al. Salivary gland neoplasms: an overview of the current WHO classification. *Head Neck Pathol*. 2021;15(2):394-406.